James A Gallagher Selected Research

Homogentisate 1,2-Dioxygenase (Homogentisate 1,2 Dioxygenase)

7/2022	Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.
3/2021	Expression of tyrosine pathway enzymes in mice demonstrates that homogentisate 1,2-dioxygenase deficiency in the liver is responsible for homogentisic acid-derived ochronotic pigmentation.
1/2020	Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
12/2019	Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria.
9/2015	Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.
1/2015	Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice.
1/2014	Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
5/2013	Recent advances in management of alkaptonuria (invited review; best practice article).
10/2010	Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James A Gallagher Research Topics

Disease

30	Alkaptonuria 07/2022 - 10/2010
13	Ochronosis 01/2021 - 11/2010
3	Osteoarthritis 01/2020 - 06/2015
3	Inborn Genetic Diseases (Disease, Hereditary) 12/2019 - 11/2010
2	Disease Progression 01/2022 - 01/2020
2	Spondylarthropathies 01/2021 - 01/2021
2	Tyrosinemias (Tyrosinemia) 01/2020 - 01/2019
2	Joint Diseases (Joint Disease) 01/2014 - 02/2011
2	Inflammation (Inflammations) 05/2008 - 01/2003
1	Rare Diseases (Rare Disease) 01/2020
1	Tyrosinosis 01/2020
1	Bone Fractures (Bone Fracture) 01/2017
1	Stress Fractures (Stress Fracture) 03/2016
1	Bone Resorption 06/2015
1	Bone Diseases (Bone Disease) 06/2015
1	Cartilage Diseases (Cartilage Disease) 06/2015
1	Osteosarcoma (Osteogenic Sarcoma) 10/2014
1	Metabolic Diseases (Metabolic Disease) 01/2014
1	Psoriasis (Pustulosis Palmaris et Plantaris) 05/2008
1	Necrosis 09/2005

Drug/Important Bio-Agent (IBA)

19	Homogentisic AcidIBA 01/2021 - 11/2010
16	nitisinone (Orfadin)FDA Link 05/2022 - 01/2014
10	Tyrosine (L-Tyrosine)FDA Link 07/2022 - 02/2011
9	Homogentisate 1,2-Dioxygenase (Homogentisate 1,2 Dioxygenase)IBA 07/2022 - 10/2010
7	EnzymesIBA 07/2022 - 02/2011
3	CollagenIBA 01/2021 - 12/2011
2	Phenylalanine (L-Phenylalanine)FDA Link 01/2020 - 01/2015
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 09/2015
2	PolymersIBA 01/2014 - 05/2013
2	Melanins (Melanin)IBA 05/2013 - 11/2010
2	Adenosine Triphosphate (ATP)IBA 05/2008 - 01/2003
1	Neurotransmitter Agents (Neurotransmitter)IBA 05/2022
1	Amino Acids FDA Link 01/2020
1	Dietary ProteinsIBA 01/2020
1	4-hydroxyphenylpyruvic acidIBA 01/2019
1	DioxygenasesIBA 01/2019
1	Purinergic P2X7 ReceptorsIBA 03/2016
1	Diphosphonates (Bisphosphonates)IBA 06/2015
1	Cathepsin KIBA 06/2015
1	Adiponectin ReceptorsIBA 10/2014
1	beta-cyclodextrin tetradecasulfate (CTDS)IBA 02/2011
1	AntioxidantsIBA 10/2010
1	CalciumIBA 05/2008
1	BradykininIBA 05/2008
1	Parathyroid Hormone-Related ProteinIBA 05/2008
1	Interleukin-1beta (Interleukin 1 beta)IBA 09/2005
1	Dinoprostone (PGE2)FDA Link 09/2005
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 09/2005
1	CytokinesIBA 09/2005
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2005
1	Purinergic Receptors (Receptors, Purine)IBA 01/2003

Therapy/Procedure

8	Therapeutics 01/2021 - 06/2015
1	Arthroplasty 01/2021
1	Diet Therapy (Therapy, Diet) 01/2020
1	Replacement Arthroplasty 01/2017